Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-24-131097
Filing Date
2024-11-26
Accepted
2024-11-26 16:57:49
Documents
9
Effectiveness Date
2024-11-26

Document Format Files

Seq Description Document Type Size
1 S-8 s-8_inducement_plan.htm S-8 151961
2 EX-5.1 kytx-ex5_1.htm EX-5.1 27352
3 EX-10.2 kytx-ex10_2.htm EX-10.2 98205
4 EX-10.3 kytx-ex10_3.htm EX-10.3 64016
5 EX-23.1 kytx-ex23_1.htm EX-23.1 4023
6 EX-FILING FEES kytx-exfiling_fees.htm EX-FILING FEES 28014
7 GRAPHIC img89746796_0.jpg GRAPHIC 5653
8 GRAPHIC img89746796_1.jpg GRAPHIC 18442
9 GRAPHIC img89746796_2.jpg GRAPHIC 4032
  Complete submission text file 0000950170-24-131097.txt   413826
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-283489 | Film No.: 241505049
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)